ArticlePatient preference and adherence2022

Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).

Marina B Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.